BEVERLY HILLS, Calif., Aug. 19 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is proud to announce that an Oxis sponsored safety study of ergothioneine was published online on July 30, 2010 by the prestigious peer reviewed journal, TOXICOLOGY. The study, utilizing the well known "Ames Test" was conducted by researchers from the American Institute of Biomedical Research (Puyallup, WA) and Toxi-Coop Zrt. (Budapest, Hungary) and clearly demonstrated the absence of any mutagenic effect associated with ergothioneine in the study model. The study will be in print shortly in a special nutraceutical issue of TOXICOLOGY.
In a letter to Dr. Alexander Schauss, lead researcher on the study, Dr. Kendall B. Wallace, PhD, Managing Editor of TOXICOLOGY, stated, "Your accepted paper is considered to be a significant contribution to the field of toxicology and we appreciate the opportunity to publish it in this journal."
"This study represents the continuing commitment by Oxis to further solidifying the already extensive foundation of safety and efficacy studies supporting the unique nutraceutical compound, ergothioneine," stated Bernie Landes, President of Oxis. "This is an important milestone in our plans to introduce a wide range of proprietary and uniquely beneficial ergothioneine based products, including dietary supplements, functional foods and beverages and personal care products," Landes added.
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to provide superior solutions to health challenges associated with oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase),
|SOURCE OXIS International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved